National Advertising Division Finds Certain Claims for Amazentis SA’s Mitopure Cellular Nutrition Supported, Recommends Others be Modified or Discontinued
New York, NY – May 8, 2025 – As part of its routine marketplace monitoring, BBB National Programs’ National Advertising Division found certain claims for Amazentis SA's Mitopure Cellular Nutrition supported but recommended other cellular performance and muscle function claims be modified or discontinued.
Mitopure Cellular Nutrition is a dietary supplement developed to counteract age-related decline in muscle and cellular health. In support of its claims, Amazentis submitted numerous studies on the impact of aging on muscle function as well as of exercise on muscle function in older populations.
The National Advertising Division (NAD) examined whether the studies demonstrate that Mitopure, when taken as directed, provides the claimed benefits.
However, regarding the claim, “Mitopure® is the first nutrient clinically-proven to trigger a crucial recycling process within our cells called mitophagy, preventing age-related cellular decline,” NAD noted that the evidence submitted was not a good fit for the challenged claims for several reasons and recommended that this claim be modified to remove the reference to “first.”
NAD recommended that the claims “boost muscle function” and “Muscle strength increases by up to 12% in 16 weeks” be modified to reflect the results of the study, i.e., hamstring muscle in obese, sedentary middle-aged adults, and that the context of the advertising in which it appears should avoid conveying that the results reflect what slim or athletically-built adults can achieve.
NAD also found that the submitted studies did not support the claim “Muscle endurance increases by up to 15% after 8 weeks because the dose was twice the recommended dose” and recommended it be discontinued.
During the inquiry, Amazentis agreed to modify the challenged claim “Muscle strength increases by up to 21% in 16 weeks” to reflect the results of a submitted study. The voluntarily discontinued claim will be treated, for compliance purposes, as though NAD recommended it be discontinued.
In its advertiser statement, Amazentis stated that while it disagrees with elements of the NAD’s analysis, it “agrees to comply with the NAD’s recommendations.”
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.
Mitopure Cellular Nutrition is a dietary supplement developed to counteract age-related decline in muscle and cellular health. In support of its claims, Amazentis submitted numerous studies on the impact of aging on muscle function as well as of exercise on muscle function in older populations.
The National Advertising Division (NAD) examined whether the studies demonstrate that Mitopure, when taken as directed, provides the claimed benefits.
Cellular Performance Claims
NAD found that the submitted studies are sufficiently reliable and provide a reasonable basis for the “Clinically proven to revitalize mitochondria” portion of the longer claim “Clinically proven to revitalize mitochondria & boost muscle function.”However, regarding the claim, “Mitopure® is the first nutrient clinically-proven to trigger a crucial recycling process within our cells called mitophagy, preventing age-related cellular decline,” NAD noted that the evidence submitted was not a good fit for the challenged claims for several reasons and recommended that this claim be modified to remove the reference to “first.”
Muscle Function Claims
In support of the muscle function claims (“boost muscle function,” “Muscle strength increases by up to 12% in 16 weeks”), Amazentis relied on studies which, NAD found were not a good fit for the challenged claims.NAD recommended that the claims “boost muscle function” and “Muscle strength increases by up to 12% in 16 weeks” be modified to reflect the results of the study, i.e., hamstring muscle in obese, sedentary middle-aged adults, and that the context of the advertising in which it appears should avoid conveying that the results reflect what slim or athletically-built adults can achieve.
NAD also found that the submitted studies did not support the claim “Muscle endurance increases by up to 15% after 8 weeks because the dose was twice the recommended dose” and recommended it be discontinued.
During the inquiry, Amazentis agreed to modify the challenged claim “Muscle strength increases by up to 21% in 16 weeks” to reflect the results of a submitted study. The voluntarily discontinued claim will be treated, for compliance purposes, as though NAD recommended it be discontinued.
In its advertiser statement, Amazentis stated that while it disagrees with elements of the NAD’s analysis, it “agrees to comply with the NAD’s recommendations.”
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.